Aligos Therapeutics Inc (ALGS) - Total Assets
Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) holds total assets worth $64.56 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aligos Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see ALGS market cap for the company's overall valuation and market capitalisation.
Aligos Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Aligos Therapeutics Inc's total assets of $64.56 Million consist of 93.6% current assets and 6.4% non-current assets. Review ALGS total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Aligos Therapeutics Inc (ALGS) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aligos Therapeutics Inc's current assets represent 93.6% of total assets in 2025, an increase from 85.7% in 2018.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2025, down from 22.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aligos Therapeutics Inc Competitors by Total Assets
Key competitors of Aligos Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Aligos Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.56 | 7.56 | 6.53 |
| Quick Ratio | 2.56 | 7.56 | 6.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $36.31 Million | $124.26 Million | $166.54 Million |
Aligos Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Aligos Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.75 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | 26.3% |
| Total Assets | $88.53 Million |
| Market Capitalization | $27.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aligos Therapeutics Inc's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aligos Therapeutics Inc's assets grew by 26.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Aligos Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $88.53 Million | +26.31% |
| 2024-12-31 | $70.09 Million | -53.74% |
| 2023-12-31 | $151.53 Million | +3.30% |
| 2022-12-31 | $146.69 Million | -37.68% |
| 2021-12-31 | $235.37 Million | -11.28% |
| 2020-12-31 | $265.30 Million | +81.07% |
| 2019-12-31 | $146.52 Million | +36.01% |
| 2018-12-31 | $107.73 Million | -- |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more